Oak Thistle LLC Sells 395 Shares of Hologic, Inc. (NASDAQ:HOLX)

Oak Thistle LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,615 shares of the medical equipment provider’s stock after selling 395 shares during the quarter. Oak Thistle LLC’s holdings in Hologic were worth $1,342,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Benson Investment Management Company Inc. bought a new position in Hologic in the fourth quarter worth approximately $4,832,000. Clean Yield Group lifted its holdings in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. Czech National Bank lifted its holdings in shares of Hologic by 6.4% in the 4th quarter. Czech National Bank now owns 50,362 shares of the medical equipment provider’s stock worth $3,631,000 after purchasing an additional 3,046 shares in the last quarter. Fulton Bank N.A. acquired a new stake in Hologic in the 4th quarter valued at $287,000. Finally, Diversified Trust Co bought a new stake in Hologic during the 4th quarter valued at $506,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on HOLX shares. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday. Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Monday. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

Insiders Place Their Bets

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.75% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $70.20 on Wednesday. The business’s 50 day simple moving average is $75.61 and its 200 day simple moving average is $78.53. Hologic, Inc. has a 12 month low of $69.46 and a 12 month high of $84.67. The company has a market cap of $15.93 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 2.32 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the prior year, the firm earned $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.